Az FDA jóváhagyta az első AI eszközt a mellrák kockázatának előrejelzésére
The U.S. Food & Drug Administration granted authorization for Clarity Breast, the first AI platform that can predict a woman's breast cancer risk from routine mammogram images, enabling a commercial launch for the preventative tool this year. The platform aims to improve early detection by identifying risks that are often invisible to human radiologists.
- The AI analyzes subtle patterns in mammogram images invisible to humans, generating five-year risk scores without family history or demographic data.
- The platform works with standard 2D mammograms and was trained on millions of diverse images to avoid bias issues common in other risk models.
- In testing, half of the younger women tested showed risk levels typically seen in much older patients — challenging standard age-based screening protocols.
- Hospitals and imaging centers can start offering the service later this year, though patients will initially pay out-of-pocket until insurers get on board.
Miért fontos?
The first wave of AI medical tools is starting to make its way from the lab to actual consumers — and with powerful diagnostic and predictive capabilities, these tools may help shift medicine from its current reactive approach to a more proactive and preventative approach to healthcare.
Kapcsolódó hírek